Pharmacogenetics of ribavirin-induced anemia in hepatitis C

被引：9

作者：

Ampuero, Javier ^{[1
,2
]}

Romero-Gomez, Manuel ^{[1
,2
]}

机构：

[1] Univ Seville, Virgen del Rocio Virgen Macarena Univ Hosp, Interctr Unit Digest Dis, Seville, Spain

[2] Inst Biomed Sevilla, Ave Manuel Siurot S-N, Seville 41013, Spain

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 14期

关键词：

anemia; hepatitis C; ITPA; pharmacogenetics; ribavirin; SLC28; GENOTYPE; 1; INFECTION; GENOME-WIDE ASSOCIATION; TRIPLE THERAPY; PEGYLATED INTERFERON; DOSE REDUCTION; ITPA GENE; VIROLOGICAL RESPONSE; PROTEASE INHIBITORS; HEMOLYTIC-ANEMIA; VIRUS-INFECTION;

D O I：

10.2217/pgs.16.28

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics assesses inherited genetic differences in drug metabolic pathways and its role in medicine is growing. Ribavirin (RBV) and peginterferon were the standard of care therapy in hepatitis C virus infection during 15 years, with the addition of first-generation protease inhibitors at the beginning of 2010s. New direct-acting agents are the new standard of care, but RBV remains important in some scenarios. The main adverse effect of RBV is anemia, which requires dose reduction and even stopping treatment in some patients. Pharmacogenetics has identified ITPA and SLC28/29 genes to be closely related to RBV-induced anemia. The routine evaluation of these genes could help to identify those patients at risk of developing anemia during the hepatitis C virus treatment.

引用

页码：1587 / 1594

页数：8

共 58 条

[1] Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir [J].

Aghemo, Alessio ;

Grassi, Eleonora ;

Rumi, Maria Grazia ;

D'Ambrosio, Roberta ;

Galmozzi, Enrico ;

Degasperi, Elisabetta ;

Castaldi, Davide ;

Soffredini, Roberta ;

Colombo, Massimo .

PLOS ONE, 2014, 9 (04)

[2] Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection [J].

Ampuero, J. ;

del Campo, J. A. ;

Rojas, L. ;

Garcia-Lozano, R. J. ;

Buti, M. ;

Sola, R. ;

Forns, X. ;

Moreno-Otero, R. ;

Andrade, R. ;

Diago, M. ;

Salmeron, J. ;

Rodrigo, L. ;

Pons, J. A. ;

Navarro, J. M. ;

Calleja, J. L. ;

Garcia-Samaniego, J. ;

Garcia-Valdecasas, M. ;

Rojas, A. ;

Millan, R. ;

Gonzalez-Escribano, M. F. ;

Romero-Gomez, M. .

GENES AND IMMUNITY, 2015, 16 (05) :297-300

[3] Review article: HCV genotype 3 - the new treatment challenge [J].

Ampuero, J. ;

Romero-Gomez, M. ;

Reddy, K. R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (07) :686-698

[4] Hepatitis C Virus Current and Evolving Treatments for Genotypes 2 and 3 [J].

Ampuero, Javier ;

Romero-Gomez, Manuel .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2015, 44 (04) :845-+

[5] Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment [J].

Ampuero, Javier ;

Antonio Del Campo, Jose ;

Rojas, Lourdes ;

Luis Calleja, Jose ;

Cabezas, Joaquin ;

Lens, Sabela ;

Crespo, Javier ;

Forns, Xavier ;

Andrade, Raul J. ;

Fernandez, Inmaculada ;

Buti, Maria ;

Millan, Raquel ;

Romero-Gomez, Manuel .

JOURNAL OF CLINICAL VIROLOGY, 2015, 68 :56-60

[6] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[7] IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C [J].

Chayama, Kazuaki ;

Hayes, C. Nelson ;

Abe, Hiromi ;

Miki, Daiki ;

Ochi, Hidenori ;

Karino, Yoshiyasu ;

Toyota, Joji ;

Nakamura, Yusuke ;

Kamatani, Naoyuki ;

Sezaki, Hitomi ;

Kobayashi, Mariko ;

Akuta, Norio ;

Suzuki, Fumitaka ;

Kumada, Hiromitsu .

JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (01) :84-93

[8] Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus [J].

Chung, Raymond T. ;

Davis, Gary L. ;

Jensen, Donald M. ;

Masur, Henry ;

Saag, Michael S. ;

Thomas, David L. ;

Aronsohn, Andrew I. ;

Charlton, Michael R. ;

Feld, Jordan J. ;

Fontana, Robert J. ;

Ghany, Marc G. ;

Godofsky, Eliot W. ;

Graham, Camilla S. ;

Kim, Arthur Y. ;

Kiser, Jennifer J. ;

Kottilil, Shyam ;

Marks, Kristen M. ;

Martin, Paul ;

Mitruka, Kiren ;

Morgan, Timothy R. ;

Naggie, Susanna ;

Raymond, Daniel ;

Reau, Nancy S. ;

Schooley, Robert T. ;

Sherman, Kenneth E. ;

Sulkowski, Mark S. ;

Vargas, Hugo E. ;

Ward, John W. ;

Wyles, David L. .

HEPATOLOGY, 2015, 62 (03) :932-954

[9] Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy [J].

Clark, P. J. ;

Aghemo, A. ;

Degasperi, E. ;

Galmozzi, E. ;

Urban, T. J. ;

Vock, D. M. ;

Patel, K. ;

Thompson, A. J. ;

Rumi, M. G. ;

D'Ambrosio, R. ;

Muir, A. J. ;

Colombo, M. .

JOURNAL OF VIRAL HEPATITIS, 2013, 20 (12) :858-866

[10] VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia [J].

Cusato, Jessica ;

Allegra, Sarah ;

Boglione, Lucio ;

De Nicolo, Amedeo ;

Cariti, Giuseppe ;

Di Perri, Giovanni ;

D'Avolio, Antonio .

PHARMACOGENETICS AND GENOMICS, 2015, 25 (04) :164-172

← 1 2 3 4 5 6 →